It’s always fascinating to listen to two of the recognized experts and leading clinicians in Cushing’s disease discuss their experiences with the disease and patients. In this Live Talk session, Pituitary World New’s innovative program for education and awareness, Dr. Kevin Yuen and Dr. Lewis Blevins bring an intimate, revealing look at their approaches to Cushing’s disease and syndrome. The discussion focuses on their experiences and how they think about their patients, and the options they have available for treatment. Listen and learn their views on each available drug to treat the disease and their rationale for recommending treatment options. And don’t miss the discussion on access to those medications, including insurance coverage issues, towards the end of the session. Enjoy!
From Lewis S Blevins Jr, MD – I’ve seen a few instances over my career of auto-immune and inflammatory disorders flaring or becoming more apparent after someone has entered remission for Cushing’s syndrome. In each
From Lewis S. Blevins, Jr. MD – Somatostatin analogs are a class of drugs that are chemically modified forms of native somatostatin. They are meant to act like somatostatin. Somatostatin is produced in our bodies,
From Lewis S. Blevins Jr, MD – One of the greatest challenges facing medical practitioners is in the recognition and diagnosis of Cushing’s syndrome and disease. As if this not sufficiently difficult, an even greater
From Lewis S. Blevins Jr, MD – Transphenoidal pituitary surgery is the treatment of choice In the setting of Cushing’s disease due to a well-defined pituitary adenoma. Occasionally, patients with a suspected pituitary adenoma, but
From Lewis S Blevins Jr., MD – Twenty-four hour urine collections are often employed to estimate the production rates of various hormones. The accuracy of test results depends entirely on the proper collection of the
From Lewis S Blevins, Jr. MD – All too often, I see patients who come to the clinic with devastating recurrences of their pituitary tumors. For example, the accompanying MRI depicts a recurrent pituitary tumor in